UDG Healthcare plc ("the Group"), a leading international healthcare services provider, will issue its interim results for the half year ended 31 March 2017 at 07:00am (BST) on Tuesday 23 May 2017.
Brendan McAtamney, CEO and Alan Ralph, CFO will be hosting a presentation for analysts and investors at the London Stock Exchange at 08:30am (BST) to discuss the company's half year results and provide an update on each of the Group's divisions.
Analysts and investors wishing to attend are asked to contact Powerscourt on the details below, as all attendees need to be pre-registered. The presentation will also be available via live audio webcast and conference call, the details of which are below.
Conference call dial-in details:
United States of America
For further information, please contact:
UDG Healthcare plc
Head of Investor Relations, Strategy & Corporate Communications
Lisa Kavanagh / Nick Brown
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering commercial, clinical, communications and packaging services to the healthcare industry, employing over 8,000 people with operations in 23 countries and delivering services in over 50 countries.
UDG Healthcare plc operates across three divisions: Ashfield, Sharp and Aquilant.
Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across two broad areas of activity: commercial & clinical services, and communications services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.
Sharp is a global leader in contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, operating from state of the art facilities across the US and Europe. Sharp is also a world leader in 'Track and Trace' serialisation services, which will require all prescription drugs to have a unique serial code for authentication and traceability.
Aquilant is a leading provider of outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK, Ireland and the Netherlands.
The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.
For more information, please go to: www.udghealthcare.com